Microbiota, Cesarean Section, Probiotics, Dysbiosis
Conditions
Brief summary
Objectives: The gut microbiota plays pivotal role in the maintenance of human health. There are numerous factors, including the mode of delivery, that impact early gut colonization. Recent research focuses on probiotics' use in prophylaxy of gut dysbiosis in the newborns delivered by CS. We aimed to investigate whether a probiotic supplement in the newborns delivered by CS alter the pattern of gut colonization and has effect on decreasing risk of dysbiosis. Methods: a prospective, randomized trial with a control group. 150 newborns, born in 38-40 gestational age, delivered by CS were included to the study. They were randomized into 2 groups- interventional supplemented with the probiotic containing Bifidobacterium breve PB04 i Lactobacillus rhamnosus KL53A (FFBaby, IBSS BioMed SA, Poland) and control. Stool samples were obtained on 5th and 6th day of life and after one month of life, and analyzed microbiologically in the lab. Bacterial colonies' genre and species were next identified and quantified.
Detailed description
The aim of the study was to assess the effect of the probiotic supplementation on microbiota composition of the gut in healthy newborns delivered by CS. We studied colonization of GI tract on the day of discharge from hospital and after a month of life. It was a prospective, randomized trial with the control group, conducted in the Neonatal Clinic of the Jagiellonian University Hospital in Kraków, lasting from April 2014 to April 2017. The patients we recruited were randomized into 2 groups- interventional or control group. In the interventional group we supplemented the probiotic containing Bifidobacterium breve PB04 i Lactobacillus rhamnosus KL53A (FFBaby, IBSS BioMed SA, Poland) orally during the first hour of life and after 12 hours in mother's milk or formula (the total amount of the probiotic was 2 x 10 6 CFU bacteria). The permission for the clinical trial was granted by the regional medical Bioethical Committee of the Jagiellonian University. (The number of decision- KBET/46/B/2014 from the 27th of March 2014)
Interventions
DIETARY_SUPPLEMENTcontaining Bifidobacterium breve PB04, Lactobacillus rhamnosus KL53A
we supplemented the probiotic orally during the first hour of life and after 12 hours in mother's milk or formula (the total amount of the probiotic was 2 x 10 6 CFU bacteria).
Sponsors
Jagiellonian University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
The patients we recruited were randomized into 2 groups- interventional or control group. For comparison we examined the stool samples of 32 healthy newborns delivered vaginally
Eligibility
Sex/Gender
ALL
Age
1 Hours to 1 Days
Healthy volunteers
No
Inclusion criteria
38-40 gestational age, normal, healthy pregnancy, delivery by CS, good clinical condition after birth, Apgar scale- 8-10 points, proper gestational mass\> 2500g, informed consent of parents. \-
Exclusion criteria
conditions mentioned above were not fulfilled, lack of informed consent of the parents or their resignation from the study. \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| microbiota colonization | 1 month of life | Stool microbiotic composition |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| respiratory infection, gastrointestinal infection | 1 year of life | frequency of respiratory and gastrointestinal infection |
Other
| Measure | Time frame | Description |
|---|---|---|
| allergy, atopy | 1 year of life | allergy or atopy episodes |
Outcome results
None listed